TokenPost·
Tiziana Life Sciences Shares Fall About 13% After Phase 2a Results
The company said its intranasal foralumab study met both primary endpoints in patients with non-active secondary progressive multiple sclerosis.
More news
- Bitcoin.com NewsTether Says It Froze Over $1.5B From Binance Hack Within 30 Minutes
- TokenPostCamping World Expects 2026 Adjusted EBITDA Below Prior Range After Q3 Loss
- TokenPosti-80 Gold Sees 2026 Output in Lower Half of Guidance Range
- TokenPostTrump Endorses Harriet Hageman to Replace Cynthia Lummis in Senate
- TokenPostRed Robin’s Preliminary Q3 Comparable Revenue Rises 3.9%
- TokenPostVanEck Ties Bitcoin’s $500,000 Target to Half of Gold’s Market Cap